Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach

• Published in: Frontiers in cellular and infection microbiology Vol. 13; p. 1061937
• Main Authors: Norshidah, Harun, Leow, Chiuan Herng, Ezleen, Kamarulzaman Ezatul, Wahab, Habibah A., Vignesh, Ramachandran, Rasul, Azhar, Lai, Ngit Shin
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 14.02.2023
• Subjects: antiviral; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Biomarkers; Cellular and Infection Microbiology; Dengue - drug therapy; dengue virus; diagnostics; drug discovery; Humans; Molecular Targeted Therapy; NS2B/NS3pro; Protease Inhibitors - pharmacology; diagnostics; NS2B/NS3pro; drug discovery; antiviral; dengue virus
• ISSN: 2235-2988; 2235-2988
• DOI: 10.3389/fcimb.2023.1061937

An increase in the occurrence of viral infectious diseases is a global concern for human health. According to a WHO report, dengue virus (DENV) is one of the most common viral diseases affecting approximately 400 million people annually, with worsening symptoms in nearly 1% of cases. Both academic and industrial researchers have conducted numerous studies on viral epidemiology, virus structure and function, source and route of infection, treatment targets, vaccines, and drugs. The development of CYD-TDV or Dengvaxia ® vaccine has been a major milestone in dengue treatment. However, evidence has shown that vaccines have some drawbacks and limitations. Therefore, researchers are developing dengue antivirals to curb infections. DENV NS2B/NS3 protease is a DENV enzyme essential for replication and virus assembly, making it an interesting antiviral target. For faster hit and lead recognition of DENV targets, methods to screen large number of molecules at lower costs are essential. Similarly, an integrated and multidisciplinary approach involving in silico screening and confirmation of biological activity is required. In this review, we discuss recent strategies for searching for novel DENV NS2B/NS3 protease inhibitors from the in silico and in vitro perspectives, either by applying one of the approaches or by integrating both. Therefore, we hope that our review will encourage researchers to integrate the best strategies and encourage further developments in this area.